INNOCARE Surges Over 7% in Early Trading as Tafasitamab Receives First Prescriptions Nationwide

Deep News

Sep 30

INNOCARE (09969) saw its share price climb 7.18% in early trading, reaching HK$18.97 with trading volume of HK$135 million.

According to INNOCARE's official announcement, the company recently declared that its CD19-targeting monoclonal antibody Monjuvi® (tafasitamab) has received its first batch of prescriptions at hospitals across multiple provinces and cities nationwide, including Beijing, Shanghai, Guangdong, Heilongjiang, Fujian, Shandong, Guangxi, Anhui, Jiangxi, Hubei, and Zhejiang. This milestone marks the innovative drug's official entry into clinical application in China.

The company noted that tafasitamab is the world's first and only approved CD19 monoclonal antibody for lymphoma treatment, and China's first approved CD19 monoclonal antibody for treating relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). This breakthrough fills the domestic gap in CD19-targeted therapy and will provide DLBCL patients with enhanced treatment options.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1137739560"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137739560\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1137739560?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 10:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137739560","market":"sg","top_or_hot":-1,"title":"INNOCARE Surges Over 7% in Early Trading as Tafasitamab Receives First Prescriptions Nationwide","media":"Deep News","content":"<p>INNOCARE (09969) saw its share price climb 7.18% in early trading, reaching HK$18.97 with trading volume of HK$135 million.</p>\n<p>According to INNOCARE's official announcement, the company recently declared that its CD19-targeting monoclonal antibody Monjuvi® (tafasitamab) has received its first batch of prescriptions at hospitals across multiple provinces and cities nationwide, including Beijing, Shanghai, Guangdong, Heilongjiang, Fujian, Shandong, Guangxi, Anhui, Jiangxi, Hubei, and Zhejiang. This milestone marks the innovative drug's official entry into clinical application in China.</p>\n<p>The company noted that tafasitamab is the world's first and only approved CD19 monoclonal antibody for lymphoma treatment, and China's first approved CD19 monoclonal antibody for treating relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). This breakthrough fills the domestic gap in CD19-targeted therapy and will provide DLBCL patients with enhanced treatment options.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>INNOCARE Surges Over 7% in Early Trading as Tafasitamab Receives First Prescriptions Nationwide</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nINNOCARE Surges Over 7% in Early Trading as Tafasitamab Receives First Prescriptions Nationwide\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-09-30 10:51</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>INNOCARE (09969) saw its share price climb 7.18% in early trading, reaching HK$18.97 with trading volume of HK$135 million.</p>\n<p>According to INNOCARE's official announcement, the company recently declared that its CD19-targeting monoclonal antibody Monjuvi® (tafasitamab) has received its first batch of prescriptions at hospitals across multiple provinces and cities nationwide, including Beijing, Shanghai, Guangdong, Heilongjiang, Fujian, Shandong, Guangxi, Anhui, Jiangxi, Hubei, and Zhejiang. This milestone marks the innovative drug's official entry into clinical application in China.</p>\n<p>The company noted that tafasitamab is the world's first and only approved CD19 monoclonal antibody for lymphoma treatment, and China's first approved CD19 monoclonal antibody for treating relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). This breakthrough fills the domestic gap in CD19-targeted therapy and will provide DLBCL patients with enhanced treatment options.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688428","symbol_name":"诺诚健华","start_time":0,"source_url":"","article_id":"1137739560","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137739560","pubTimestamp":1759200679,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"INNOCARE (09969) saw its share price climb 7.18% in early trading, reaching HK$18.97 with trading volume of HK$135 million. According to INNOCARE's official announcement, the company recently...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688428":"诺诚健华","BK1574":"生物医药B类股","09969":"诺诚健华","BK0239":"医药制造","BK1161":"生物科技"},"translate_title":"随着Tafasitamab在全国范围内获得首批处方，诺诚健华早盘飙升逾7%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688428":1,"09969":1},"content_text":"INNOCARE (09969) saw its share price climb 7.18% in early trading, reaching HK$18.97 with trading volume of HK$135 million.\nAccording to INNOCARE's official announcement, the company recently declared that its CD19-targeting monoclonal antibody Monjuvi® (tafasitamab) has received its first batch of prescriptions at hospitals across multiple provinces and cities nationwide, including Beijing, Shanghai, Guangdong, Heilongjiang, Fujian, Shandong, Guangxi, Anhui, Jiangxi, Hubei, and Zhejiang. This milestone marks the innovative drug's official entry into clinical application in China.\nThe company noted that tafasitamab is the world's first and only approved CD19 monoclonal antibody for lymphoma treatment, and China's first approved CD19 monoclonal antibody for treating relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). This breakthrough fills the domestic gap in CD19-targeted therapy and will provide DLBCL patients with enhanced treatment options.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}